UMC UTRECHT
UMC Utrecht is a leading international university medical center generating, testing, sharing, and applying knowledge on health, illness, and health care for the benefit of patients and society. Care, research and education are the three mainstays of UMC Utrecht. These mainstays are inextricably intertwined in the ongoing efforts to improve people’s health. Leading scientific research, groundbreaking innovation and collaboration with patients and other interested parties form the basis of the first-rate healthcare.
UMC Utrecht has several expertise centers to which patients and medical professionals know they should turn for oncology, neurology, cardiovascular medicine and pediatrics. Furthermore, UMC Utrecht takes the lead in the wide-ranging field of prevention of infections and chronic inflammatory diseases like rheumatism. UMC Utrecht is also known for regenerative medicine, an innovative field in which they provide new treatments for hematologic disorders, cartilage and cardiac valve problems. All basic specializations are represented in the hospital, in addition to the centers in the above-mentioned fields.
UMC UTRECHT & WILHELMINA CHILDREN’S HOSPITAL FOUNDATION
At UMC Utrecht and the Wilhelmina Children’s Hospital, we are committed to delivering the very best care for people of all ages. The UMC Utrecht & Wilhelmina Children’s Hospital Foundation makes this possible with the help of donors, companies, and foundations. Together, we fund pioneering research, innovative treatments, and a hospital environment where children can truly feel at ease.
Every contribution counts. Your support today can change lives tomorrow.
LOBULAIR BREAST CANCER RESEARCH
Invasive Lobular Breast Cancer (ILC) accounts for up to 15% of all breast cancers and is a unique breast cancer type. ILC is hard to detect ILC through standard screening. Although most ILCs respond well to endocrine treatment, a third of the patients will eventually develop metastatic disease. At this stage, tumors often not respond to standard therapies, resulting in a poor prognosis. This has to change.Since 2003, researchers at the UMC Utrecht have performed ground-breaking studies studying all aspects of ILC, from the development and progression of the disease, development of diagnostic biomarkers, and towards new options for treatment. Our ILC researchers chair the largest ILC consortium in the World (www.elbcc.org) and actively strive to improve ILC awareness and communication towards patients. We believe that our multi-disciplinary preclinical approach and translation of fundamental research will lead to better diagnosis and treatment of patients suffering from ILC.
STEM CELL NOSE DROPS FOR BABIES WITH BRAIN INJURY
Every year, around 300 newborn babies suffer brain damage around the time of birth – a rare occurrence, but one that can have serious and lasting consequences. Until now, treatments have focused on preventing brain damage, but often we are too late, and few effective options are available. However, groundbreaking research offers new hope for a treatment that may actually help these babies.
Brain damage in newborn babies can occur due to oxygen deprivation or a stroke shortly after birth. Previous laboratory research has shown that donor stem cells can stimulate the brain to repair itself. However, injecting stem cells directly into the brain is too invasive for newborns. That’s why, in recent years, we have developed stem cell nose drops as an alternative.
Recent research involving ten babies who suffered a stroke has shown that administering stem cells via nose drops is safe. The treatment appears promising in terms of developmental progress, though its full effectiveness still needs to be demonstrated. With this research, we are taking an important step toward a future in which brain damage in newborns does not automatically lead to lifelong disability. By combining innovative treatments like stem cell nose drops with careful clinical research, we are offering new hope to these vulnerable children and their families. Together, we are getting ever closer to our dream: a safe and effective treatment for brain injury in babies.
RESEARCH FOR METABOLIC DISEASE PPA2
Floris and Tessa have the metabolic disease PPA2. Due to a fault in their DNA, their hearts can suddenly fail or develop life-threatening arrhythmias. Every day, they live with this threat – even a simple cold can have severe consequences.
Thankfully, there is hope: groundbreaking research is now starting at the Wilhelmina Children’s Hospital to repair this genetic fault. Led by Professor Sabine Fuchs, new techniques such as base editing and prime editing are being tested. This gives hope that one day, a lasting treatment will be available for children like Floris and Tessa.
But this research still needs additional support. We are determined to do everything we can to ensure this study can continue. Will you help? Together, we can create a future where children with PPA2 no longer have to live in fear.
For more information please contact
Mathilda Cremer
UMC Utrecht & Wilhelmina Children’s Hospital Foundation
m.b.cremer@umcutrecht.nl
1. PAY BY CREDIT CARD
2. PAY BY CHECK
To make a gift to the Friends of UMC Utrecht Fund at the Netherland-America Foundation, please complete this form and make a check payable to “The Netherland-America Foundation”. Please mail your check to:
The Netherland-America Foundation
505 8th Avenue, Ste 12A-05
New York, NY 10018
3. DONATE SHARES OF STOCK
Contact the NAF at 212-825-1221 or info@thenaf.org.
TAX-DEDUCTIBILITY
FOR U.S. TAXES The Netherland-America Foundation, Inc. is a 501(c) 3 not-for-profit organization. All contributions are tax-deductible for the purpose of U. S. federal and state taxes, to the extent permitted by federal and state law. CHARITY NAVIGATOR Charity Navigator, America’s premier charity evaluator, gave the NAF a 4-star rating-their highest-for “its ability to efficiently manage and grow its finances, demonstrating to the public it is worthy of their trust,”
Our Sponsors
